2023
Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Robison T, Widgerow A. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 23: 1266-1270. PMID: 38206144, DOI: 10.36849/jdd.7622.Peer-Reviewed Original ResearchConceptsFacial dyschromiaMulti-center trialClinical studiesBlinded clinical studyTopical productsALS cohortExtension studyHydroquinone 4%Follow-up visitExtension phaseClearance of pigmentAssociated with increased productionMulti-centerDaily sunscreen useReduced clearanceCohortDyschromiaSunscreen useIn vitroWeeksTrialsLong-term basisSignificant reboundSkinEfficacyA Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 22: 333-338. PMID: 37026875, DOI: 10.36849/jdd.7340.Peer-Reviewed Original ResearchConceptsModified Melasma Area Severity IndexHydroquinone 4%Post-inflammatory hyperpigmentationFacial dyschromiaBlinded clinical studyFollow-upClinical studiesTopical productsAdverse eventsModified melasma area severity index scoreMulti-centerMelasma Area Severity IndexArea Severity IndexNo adverse eventsClearance of pigmentIn vitro studiesExcessive sun exposureBlinded investigatorRight cheekWeek 4Griffiths ScalesReduced clearanceSun exposureMedical disordersTolerability assessments
2015
Contact Dermatitis and Topical Agents
Cohen D, Price A, Ramachandran S. Contact Dermatitis and Topical Agents. 2015, 52-64. DOI: 10.1002/9781118655566.ch6.Peer-Reviewed Original Research
2004
Patch testing for corticosteroid allergy.
el-Azhary R, Warshaw E, Watsky KL. Patch testing for corticosteroid allergy. Dermatitis 2004, 15: 91-4. PMID: 15473336.Peer-Reviewed Original ResearchConceptsCorticosteroid allergyContact allergyVeterans Affairs Medical CenterTopical corticosteroid allergyDepartment of DermatologyAssociate Clinical ProfessorTopical corticosteroidsCommon allergensCounter medicationsMayo ClinicProfessor of DermatologyMedical CenterYale University SchoolAllergyAllergen substitutionDermatologic therapyCorticosteroidsTopical productsDermatologyClinical ProfessorAllergensUniversity SchoolSection chiefsUniversity of MinnesotaSaint Raphael
2003
Intolerance to topical products may be due to dermographism.
Watsky KL, McGovern T. Intolerance to topical products may be due to dermographism. Dermatitis 2003, 14: 35-6. PMID: 14744421, DOI: 10.2310/6620.2003.38772.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply